Published in Women's Health Weekly, March 1st, 1995
Alendronate was given to 516 women over three years, producing an average 6.8 percent increase in bone density at the spine, said Merck & Co., which plans next month to submit it for Food and Drug Administration approval.
Patients in the trials in 15 countries outside the United States also showed 4.8 percent and 6.9 percent increases at the two spots on the hip most prone to fracture.
"That's pretty substantial," said Richard Gelula of the National Osteoporosis Foundation in Washington. "If they can reduce...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.